Full-Time
Posted on 8/10/2026
Markets real-time CGM devices and analytics
$71.6k - $119.3k/yr
Company Does Not Provide H1B Sponsorship
Virginia, USA
Remote
Remote home office; travel required 15–25%.
Bachelor's
See people who can refer or advise you
Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Professional Development Budget
Remote Work Options
Flexible Work Hours
Tuition Reimbursement
Dexcom, Health2Sync partner on diabetes care in Asia. Mon, 24th Aug 2026 (Today) Dexcom and Health2Sync have formed a partnership focused on diabetes care in Australia and Singapore, linking glucose monitoring with digital chronic disease management. The partnership aims to support more connected care for people living with diabetes and their healthcare providers in both markets. It also reflects a broader push to expand digital health tools across Asia-Pacific. Health2Sync operates a digital chronic disease management platform that supports about 1.7 million users across the region. The company has built a presence in several Asian markets by offering tools that help people with diabetes and healthcare teams manage long-term care through digital services. Dexcom is known for its continuous glucose monitoring systems, which track glucose levels for people living with diabetes. The tie-up with Health2Sync reflects growing demand for connected healthcare technologies that support care coordination, simplify clinical workflows and enable more tailored approaches to chronic disease management. Regional push The deal gives Dexcom another partnership in Asia-Pacific as digital health companies seek to integrate monitoring devices with software platforms used by patients and clinicians. Australia and Singapore are both exploring greater use of remote monitoring and data-driven management for chronic conditions. Diabetes remains a major long-term health issue across the region, driving demand for systems that connect patient data with clinical decision-making. Companies in the sector have increasingly focused on linking devices, apps and care teams rather than offering standalone products. Health2Sync's scale in the region may give Dexcom access to a wider digital care network, while Dexcom's monitoring products add a stream of glucose data that can be incorporated into patient management. The companies have not disclosed commercial terms or product integration details. The announcement did not specify which Dexcom products or Health2Sync services would be included first in Australia and Singapore. It also did not say when any integrated offering would become available to users or healthcare providers. Company comments Both companies framed the partnership around a shared view that diabetes care can benefit from more connected management models. They said the arrangement is intended to help healthcare professionals and people living with diabetes access smarter, more connected ways to manage the condition. No financial details were released. The companies also did not outline any regulatory steps, local distribution arrangements or clinical partnerships tied to the agreement. More information is expected later. For now, the main disclosed fact is that Dexcom and Health2Sync are aligning their diabetes-related offerings across Australia and Singapore.
Silvant Capital Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 79,562 shares of the medical device company’s stock, valued at approximately $5,359,000. Other large investors have also recently modified their holdings of the company. Reflection Asset Management acquired a new […]
DexCom shares have surged 52.5% over the past three months, significantly outpacing the broader market's 2.4% gain and its medical sector's 10.4% rise. The rally followed strong second-quarter results. Revenue increased 13.1% year-over-year to $1.31 billion, whilst adjusted earnings of 70 cents per share beat consensus estimates of 61 cents. US revenues rose 11% to $933.4 million, and international revenues jumped 19% to $375 million. Margin expansion bolstered the growth story. Adjusted gross margin reached 64.1%, up 400 basis points year-over-year, whilst adjusted operating margin improved 590 basis points to 25.1%. DexCom now trades at 30.7 times forward earnings, above its sub-industry average of 27.3 times. The premium valuation means future gains will depend on sustained earnings delivery and market access expansion rather than multiple expansion.
DexCom reported 12% organic revenue growth in Q2 2026, driven by record customer acquisition and market share gains. The company raised full-year guidance by over 50 basis points despite a projected $15 million foreign exchange headwind. The CONNECT trial showed 1.6% A1C improvement for non-insulin type 2 diabetes users, supporting reimbursement expansion. DexCom secured coverage for over 7 million non-insulin patients across the four largest US commercial pharmacy benefit managers. The company acquired Nutrisense to integrate nutrition-focused AI insights into its product ecosystem. DexCom executed $600 million of its $1 billion share repurchase programme during the quarter. Gross margins improved 400 basis points year-over-year to 64.1%, driven by manufacturing efficiencies. The company targets converting approximately 50% of US customers to its G7 15-day system by year-end 2026.
DexCom Inc reported strong second-quarter 2026 results, with worldwide revenue of $1.31 billion, up 13% year-over-year. US revenue reached $933 million (up 11%) whilst international revenue grew 19% to $375 million. Gross profit margin improved significantly to 64.1%, up from 60.1% in Q2 2025, driven by manufacturing efficiencies and the transition to the G7 15-day system. Operating income rose to $328.3 million, representing 25.1% of revenue. Net income increased 46% year-over-year to $269.1 million, or $0.70 per share. The company generated over $600 million in free cash flow in the first half of 2026, more than double the prior year period. DexCom raised its full-year 2026 revenue guidance to $5.18 billion to $5.25 billion, representing 11%-13% growth. The company also increased gross margin guidance to approximately 64% and operating margin guidance to 23.5%-24%.